Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

被引:0
作者
T D Gould
J A Quiroz
J Singh
C A Zarate
H K Manji
机构
[1] Laboratory of Molecular Pathophysiology,
[2] National Institute of Mental Health,undefined
来源
Molecular Psychiatry | 2004年 / 9卷
关键词
depression; mania; pharmacology; manic-depressive illness; neurotrophic factors; valproic acid; PAP phosphatase; pramipexole; zinc;
D O I
暂无
中图分类号
学科分类号
摘要
Bipolar disorder afflicts approximately 1–3% of both men and women, and is coincident with major economic, societal, medical, and interpersonal consequences. Current mediations used for its treatment are associated with variable rates of efficacy and often intolerable side effects. While preclinical and clinical knowledge in the neurosciences has expanded at a tremendous rate, recent years have seen no major breakthroughs in the development of novel types of treatment for bipolar disorder. We review here approaches to develop novel treatments specifically for bipolar disorder. Deliberate (ie not by serendipity) treatments may come from one of two general mechanisms: (1) Understanding the mechanism of action of current medications and thereafter designing novel drugs that mimics these mechanism(s); (2) Basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder. In this review, we focus upon the first approach. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes where lithium competes for a magnesium binding site (inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3 (GSK-3), fructose 1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), valproate inhibitable enzymes (succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, histone deacetylase), targets of carbamazepine (sodium channels, adenosine receptors, adenylate cyclase), and signaling pathways regulated by multiple drugs of different classes (phosphoinositol/protein kinase C, cyclic AMP, arachidonic acid, neurotrophic pathways). While the task of developing novel medications for bipolar disorder is truly daunting, we are hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
引用
收藏
页码:734 / 755
页数:21
相关论文
共 945 条
  • [1] Calabrese JR(2003)Impact of bipolar disorder on a U.S. community sample J Clin Psychiatry 64 425-432
  • [2] Hirschfeld RM(2000)The economic burden of bipolar disease J Clin Psychiatry 61 38-41
  • [3] Reed M(2003)Social and economic burden of mood disorders Biol Psychiatry 54 208-215
  • [4] Davies MA(2003)Insurance expenditures on bipolar disorder: clinical and parity implications Am J Psychiatry 160 1286-1290
  • [5] Frye MA(2003)[Bipolar I disorder in France: prevalence of manic episodes and hospitalisation-related costs] Encephale 29 248-253
  • [6] Keck PE(2003)Costs of bipolar disorder Pharmacoeconomics 21 601-622
  • [7] Woods SW(2003)Mood disorders and medical illness: a major public health problem Biol Psychiatry 54 177-180
  • [8] Simon GE(2003)Safety of available agents used to treat bipolar disorder: focus on weight gain J Clin Psychiatry 64 532-539
  • [9] Peele PB(2002)Antiepileptic drugs in psychiatry-focus on randomized controlled trial Epilepsy Res 50 195-202
  • [10] Xu Y(2003)Atypical antipsychotics in the treatment of bipolar disorder Expert Opin Pharmacother 4 751-760